The expanding clinical application of CDK4‐ and CDK6‐inhibiting drugs in the managements of breast cancer has raised a great interest in testing these drugs in other neoplasms. The potential of combining these drugs with other therapeutic approaches seems to be an interesting work‐ground to explore. Even though a potential integration of CDK4 and CDK6 inhibitors with radiotherapy (RT) has been hypothesized, this kind of approach has not been sufficiently pursued, neither in preclinical nor in clinical studies. Similarly, the most recent discoveries focusing on autophagy, as a possible target pathway able to enhance the antitumor efficacy of CDK4 and CDK6 inhibitors is promising but needs more investigations. The aim of this review is to discuss the recent literature on the field in order to infer a rational combination strategy including cyclin‐D1/CDK4‐CDK6 inhibitors, RT, and/or other anticancer agents targeting G1‐S phase cell cycle transition.

Nardone, V., Barbarino, M., Angrisani, A., Correale, P., Pastina, P., Cappabianca, S., et al. (2021). CDK4, CDK6/cyclin‐d1 complex inhibition and radiotherapy for cancer control: a role for autophagy. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 22(16), 1-18 [10.3390/ijms22168391].

CDK4, CDK6/cyclin‐d1 complex inhibition and radiotherapy for cancer control: a role for autophagy

Barbarino M.;Pastina P.;Miracco C.;Giordano A.;Pirtoli L.
2021-01-01

Abstract

The expanding clinical application of CDK4‐ and CDK6‐inhibiting drugs in the managements of breast cancer has raised a great interest in testing these drugs in other neoplasms. The potential of combining these drugs with other therapeutic approaches seems to be an interesting work‐ground to explore. Even though a potential integration of CDK4 and CDK6 inhibitors with radiotherapy (RT) has been hypothesized, this kind of approach has not been sufficiently pursued, neither in preclinical nor in clinical studies. Similarly, the most recent discoveries focusing on autophagy, as a possible target pathway able to enhance the antitumor efficacy of CDK4 and CDK6 inhibitors is promising but needs more investigations. The aim of this review is to discuss the recent literature on the field in order to infer a rational combination strategy including cyclin‐D1/CDK4‐CDK6 inhibitors, RT, and/or other anticancer agents targeting G1‐S phase cell cycle transition.
Nardone, V., Barbarino, M., Angrisani, A., Correale, P., Pastina, P., Cappabianca, S., et al. (2021). CDK4, CDK6/cyclin‐d1 complex inhibition and radiotherapy for cancer control: a role for autophagy. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 22(16), 1-18 [10.3390/ijms22168391].
File in questo prodotto:
File Dimensione Formato  
641_CDK4 CDK6 cyclin-D1 Complex Inhibition and Radiotherapy for Cancer Control.pdf

accesso aperto

Descrizione: Articolo
Tipologia: PDF editoriale
Licenza: Creative commons
Dimensione 1.45 MB
Formato Adobe PDF
1.45 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/1152960